Insider transaction details
On February 18, 2026, Exelixis, Inc. (NASDAQ: EXEL) director Jack L. Wyszomierski sold 99,574 shares of the company's common stock for approximately $4.38 million. The disposals were executed at prices between $43.32 and $44.49 per share.
Also on February 18, Wyszomierski exercised stock options to acquire 20,634 shares of Exelixis common stock at an exercise price of $19.77 per share, for a total cash outlay of $407,934.
Post-transaction holdings and plan mechanics
After completing the sale and exercise, Wyszomierski directly holds 279,942 shares of Exelixis common stock. That total includes 9,812 shares that will be issued upon the vesting of restricted stock units.
The sales were executed under a Rule 10b5-1 trading plan that Wyszomierski adopted on November 19, 2025.
Company metrics referenced
Exelixis is a biotechnology company with a market capitalization of $11.3 billion and a reported price-to-earnings ratio of 15.7, a level described in available data as being below its Fair Value estimate. The company is reported to have been profitable over the last twelve months, with a return on equity of 36%.
Recent financial results
In its fourth-quarter 2025 results, Exelixis posted earnings per share of $0.97, beating the consensus forecast of $0.80. That EPS result represents a 21.25% increase over the forecast figure. Revenue for the quarter, however, came in at $598.66 million, short of the anticipated $604.56 million.
Analyst reactions and drug program notes
Following the results, H.C. Wainwright raised its price target for Exelixis from $52 to $54 while maintaining a Buy rating, citing lower-than-expected tax expenses as a factor behind the earnings beat. Separately, Citizens reaffirmed a Market Outperform rating and maintained a $50 price target, pointing to optimism around Exelixis's cancer drug zanzalintinib. The research firm highlighted the drug's potential in treating metastatic colorectal cancer, particularly after discussions at the ESMO 2025 meeting.
Context for investors
Investors seeking additional analysis may consult comprehensive research reports available for EXEL and a broad set of U.S. equities. The combination of insider activity, recent quarterly results showing an EPS beat but a revenue shortfall, and evolving analyst price targets collectively contribute to the near-term information set investors may use when evaluating the company.